Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib-Reference-Cited by-同舟云学术

Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib

Published:2021-04 Issue: Volume:154 Page:216-218
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Wang Yan-li,Wu Zhen-zhen,Zhang Heng-rui,Chen Dong-sheng,Zhao Xin

Funder

National Natural Science Foundation of China

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference5 articles.

1. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer;Solomon;J. Thorac. Oncol.,2009

2. Differential crizotinib response duration among ALK fusion variants in ALK-Positive non-small-cell lung cancer;Yoshida;J. Clin. Oncol.,2016

3. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology;Hallberg;Nat. Rev. Cancer,2013

4. Coexistence of a novel PRKCB-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to Crizotinib;Luo;J. Thorac. Oncol.,2019

5. A novel intergenic region between CENPA and DPYSL5-ALK exon 20 fusion variant responding to crizotinib treatment in a patient with lung adenocarcinoma;Fei;J. Thorac. Oncol.,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RNA-binding protein THUMPD2 inhibits proliferation and promotes metastasis in epithelial ovarian cancer;Heliyon;2024-07

2. Identification of key genes and biological pathways in chronic obstructive pulmonary disease using bioinformatics and next generation sequencing data analysis;2024-02-14

3. Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes;ESMO Open;2022-04